@JacobPlieth@AppleHelix You are right. I was mixing up two topics. But would note that guidance for single arm path published in 2018 and in place when study started. No reason for the FDA to dishonor that. I suppose moving forward, AA may be more challenging.
@Bakery_bros I get SGEN is expensive but it has cash flow which offers more strategic value. You think BT8009 can show superiority vs EV in H2H in mUC? I think 5% PoS.
❗️SGLT2i were described a long time ago.
✅They are now popular drugs to treat type 2 diabetes, heart failure, and chronic kidney disease.
Want to know more? Time for a 🧵
1/20